RE-TONE: Understanding Physical Performance, Recovery & Growth Hormone Research
RE-TONE is an educational resource about exercise physiology, physical performance, recovery, growth-hormone signaling, and current research involving CJC-1295 and Ipamorelin.
Physical performance is influenced by many interconnected factors, including training, nutrition, sleep, cardiovascular fitness, muscle function, genetics, age, hormones, medications, and overall health.
Researchers have investigated compounds that influence growth-hormone signaling, including CJC-1295 and Ipamorelin.
Research demonstrating an effect on growth hormone does not establish that a substance safely improves athletic performance, increases muscle mass, increases strength, or accelerates recovery in humans.
Understanding Physical Performance
Athletic and physical performance involves multiple systems working together. These can include:
Training, adaptation & recovery:
Training produces physiological stress that can lead to adaptations over time. Appropriate recovery allows the body to restore energy stores, remodel tissues, and adapt to training. These processes vary substantially among individuals.
Understanding Growth Hormone
Growth hormone, commonly abbreviated GH, is naturally produced by the pituitary gland. GH is released in pulses, with secretion influenced by factors including:
Growth hormone also stimulates production of insulin-like growth factor 1 (IGF-1), primarily in the liver and other tissues. The GH/IGF-1 system participates in normal growth, metabolism, protein regulation, tissue maintenance, and body-composition physiology.
However, involvement of GH in these normal physiological processes does not mean that increasing GH will necessarily improve physical performance or health.
CJC-1295
CJC-1295 is a synthetic peptide related to growth hormone-releasing hormone (GHRH). GHRH is naturally produced by the hypothalamus and signals the pituitary gland to release growth hormone.
Human research has demonstrated that certain forms of CJC-1295 can increase circulating GH and IGF-1. However, an increase in GH or IGF-1 does not establish that CJC-1295 improves:
FDA's Pharmacy Compounding Advisory Committee considered several forms of CJC-1295 in December 2024. The medical use evaluated by FDA was growth hormone deficiency, not athletic-performance enhancement. U.S. Food and Drug Administration
Different forms of CJC-1295 have been discussed in the research literature and compounding context, including forms with and without a drug affinity complex (DAC). These formulations should not automatically be considered interchangeable.
Ipamorelin
Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue. It acts at the ghrelin receptor and can stimulate endogenous growth-hormone release. This mechanism differs from CJC-1295, even though both substances influence the growth-hormone system.
Research involving Ipamorelin has examined growth-hormone secretion and several proposed medical applications. FDA evaluated Ipamorelin-related substances in 2024 for proposed uses involving growth hormone deficiency and postoperative ileus. FDA concluded that the available evidence weighed against adding Ipamorelin-related substances to the 503A Bulks List. U.S. Food and Drug Administration
Not established for athletic use:
Those evaluations did not establish Ipamorelin as a treatment for athletic-performance enhancement.
CJC-1295 + Ipamorelin
CJC-1295 and Ipamorelin are sometimes discussed together because they influence growth-hormone release through different biological pathways. CJC-1295 acts through the GHRH pathway, while Ipamorelin acts as a growth-hormone secretagogue through the ghrelin receptor.
FDA has documented that websites and wellness clinics have promoted the two substances together as a purportedly synergistic combination. U.S. Food and Drug Administration
That marketing rationale should not be confused with clinical evidence demonstrating that the combination safely improves athletic performance, body composition, strength, or recovery. Evidence demonstrating that two substances affect complementary biological pathways does not establish that combining them produces a clinically meaningful benefit.
Exercise & Recovery
Physical recovery is a normal component of training. Following exercise, the body may undergo processes involving:
The amount of recovery required depends upon exercise intensity, duration, training experience, age, nutrition, sleep, health status, and other factors.
Established approaches supporting exercise recovery include appropriate nutrition, hydration, sleep, progressive training, rest, and management of injuries or underlying medical conditions. Experimental peptide use should not replace these established components of training and recovery.
Understanding the Evidence
Research involving CJC-1295 and Ipamorelin includes:
Research includes:
- Laboratory research
- Animal studies
- Pharmacological studies
- Growth-hormone research
- Limited human clinical studies
Human studies demonstrate that manipulating these pathways can affect growth-hormone physiology. However:
- A biological effect is not the same as a demonstrated athletic benefit
- An increase in GH or IGF-1 does not by itself establish improvements
- Clinical trials designed for those outcomes would be necessary
Clinical trials specifically designed to evaluate those outcomes would be necessary to establish such claims.
Supporting Physical Performance
Evidence-based approaches to physical performance generally focus on fundamentals such as:
Training and nutritional requirements vary substantially according to age, health, goals, sport, and level of activity.
Regulatory & Safety Considerations
CJC-1295 and Ipamorelin are not FDA-approved treatments for improving athletic performance.
FDA currently publishes potential significant safety concerns involving both substances in the context of compounding. U.S. Food and Drug Administration
For CJC-1295, FDA identifies concerns involving potential immunogenicity, peptide-related impurities, and active pharmaceutical ingredient characterization. FDA also reports that serious adverse events associated with CJC-1295 have included increased heart rate and systemic vasodilatory reactions, while noting that available clinical data are limited. U.S. Food and Drug Administration
For Ipamorelin, FDA identifies potential immunogenicity concerns associated with aggregation and peptide-related impurities. FDA's evaluation also identified adverse events in an intravenous clinical study—including hypokalemia, insomnia, hyperglycemia, nausea, vomiting, abdominal distention and deaths—while noting that it was unclear whether the deaths were related to Ipamorelin. FDA also reported insufficient safety information for certain other injectable routes. U.S. Food and Drug Administration
FDA's 2024 review concluded that the available information weighed against adding Ipamorelin-related bulk drug substances to the 503A Bulks List. U.S. Food and Drug Administration
These distinctions are important when evaluating claims surrounding compounded or investigational peptide products.
Questions to Discuss With a Healthcare Professional
Patients learning about physical performance and peptide research may wish to ask:
Continuing Research
Growth-hormone physiology remains an active area of biomedical research. CJC-1295 research has demonstrated biological activity involving GH and IGF-1, while Ipamorelin research has examined its ability to stimulate growth-hormone secretion. These findings contribute to scientific understanding of the GH/IGF-1 system.
Patients should distinguish among normal physiology, biological mechanisms, experimental research, measurable hormone changes, clinical outcomes, and FDA-approved treatments when evaluating performance-related peptide claims.
Educational Resources & Citations
This page is provided for general educational purposes only. It is not intended to provide medical advice, diagnosis, treatment, training advice, or recommendations regarding athletic performance.
References to CJC-1295, Ipamorelin, growth hormone, IGF-1, exercise physiology, physical performance, recovery, biological mechanisms, laboratory research, animal studies, or areas of clinical investigation are provided for educational purposes and should not be interpreted as a recommendation or endorsement of a particular substance or treatment.
Discussion of CJC-1295 or Ipamorelin does not establish that either substance, individually or in combination, has been demonstrated to improve athletic performance, increase muscle mass, increase strength, improve endurance, accelerate recovery, or prevent injury.
Treatment decisions should be individualized and made with an appropriately licensed healthcare professional based on medical history, current health, medications, potential risks, available clinical evidence, and professional clinical judgment.
FDA approval status, compounding policies, clinical evidence, and regulatory requirements may change. Current information should be verified through the U.S. Food & Drug Administration and other recognized medical resources.